CRL Gears Up for Q4 Earnings: Here's What You Need to Know

Core Viewpoint - Charles River Laboratories International, Inc. (CRL) is set to report its fourth-quarter 2024 results on February 19, with expectations of mixed performance in revenue and earnings per share (EPS) compared to the previous year [1]. Revenue and Earnings Estimates - The Zacks Consensus Estimate for CRL's revenues is $977.4 million, indicating a 3.6$2.52, reflecting a 2.4% increase year over year [3]. - In the last reported quarter, CRL's adjusted EPS was $2.59, exceeding the Zacks Consensus Estimate by 6.6$2.52 per share in the past 30 days [4]. Segment Performance - The Research Models and Services (RMS) segment is projected to generate revenues of $203 million, suggesting a 3.7$563.1 million, indicating a 10% decline year over year, influenced by lower revenues in Discovery Services and Safety Assessment [12]. - The Manufacturing Solutions segment is anticipated to show revenue growth across all its businesses, with estimates of $204.7 million, reflecting a 6.6% year-over-year increase [14]. Recent Developments - CRL launched the Retrogenix Non-Human Protein Library to assist biopharmaceutical clients in assessing off-target binding, and entered into a collaboration with H. Lundbeck A/S for brain disease research [9][10]. - The company has initiated several collaborations to enhance the DSA segment, including partnerships with Autobahn Labs and CEBINA GmbH, focusing on advancing academic research in neurodegeneration [10][11]. Earnings ESP and Zacks Rank - CRL has an Earnings ESP of -0.60%, indicating a lower likelihood of beating earnings estimates [15]. - The company currently holds a Zacks Rank of 3 (Hold) [15].